NMD4C and MDC Award Fellowship Funding in NMD Research and Medicine
Together the Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC) are excited to announce the 2025 recipients of our neuromuscular fellowship funding competition to award postdoctoral fellowships in neuromuscular disease (NMD) research and clinical fellowships in neuromuscular medicine and electromyography!
Learn more about the 2025 fellows!
The 2025 competition provides salary support for three early-career scientists to conduct postdoctoral studies in laboratories focused on NMD research, and two early-career neurologists to participate in neuromuscular medicine and electromyography training programs. Successful applicants receive $40 000 in funding over a one-year period for postdoctoral fellowships, and $80 000 in funding over a one-year period for clinical fellowships. This year’s fellowship awards are made possible by the generous supporters of MDC, and one clinical fellowship through an unrestricted educational grant from Roche Canada.
This competition involves an extensive review by leading Canadian neuromuscular researchers and clinicians to ensure the top-ranked candidates are selected for this funding opportunity. From the entire neuromuscular community, congratulations to all 2025 recipients!
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.